SA
Log In
SNDX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
21 analysts·High coverage
74
Score
20 Buy (95%)1 Hold (5%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2095%
Hold
15%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$37.00
+84.1%
Consensus
$41.50
+106.5%
Bull
$46.00
+128.9%
12-Month Target Range21 analysts
$37.00$41.50$46.00
Current $20.10Consensus
Current Price
$20.10
Upside to Consensus
$21.40

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+47.41%
EPS—
FY2028
Rev+36.16%
EPS—
FY2029
Rev+30.55%
EPS+190.40%

Earnings Surprises

Recent Analyst Actions

May 4, 2026Stifel Nicolaus
Syndax price target raised to $46 from $45 at Stifel
Target:$46.00
+140.7%from $19.11
May 1, 2026Barclays
Syndax price target raised to $37 from $35 at Barclays
Target:$37.00
+72.7%from $21.43
Feb 27, 2026Stifel Nicolaus
Syndax Pharmaceuticals (SNDX) PT Raised to $45 at Stifel
Target:$45.00
+107.3%from $21.71
Nov 24, 2025Barclays
Syndax price target raised to $35 from $22 at Barclays
Target:$35.00
+100.7%from $17.44
Nov 4, 2025UBS
Syndax price target raised to $38 from $35 at UBS
Target:$38.00
+176.2%from $13.76
Nov 4, 2025Barclays
Syndax price target raised to $22 from $19 at Barclays
Target:$22.00
+59.9%from $13.76
Sep 10, 2025Stifel Nicolaus
Syndax resumed with a Buy at Stifel
Target:$44.00
+179.7%from $15.73
Jul 15, 2025UBS
Syndax price target lowered to $35 from $37 at UBS
Target:$35.00
+257.3%from $9.79
Jul 10, 2025Goldman Sachs
Syndax initiated with a Buy at Goldman Sachs
Target:$18.00
+83.3%from $9.82
Nov 13, 2024Scotiabank
Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank
Target:$18.00
-10.2%from $20.04
Oct 24, 2024UBS
UBS Starts Syndax Pharmaceuticals (SNDX) at Buy
Target:$37.00
+99.6%from $18.54
Aug 15, 2024Citigroup
Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi
Target:$34.00
+69.2%from $20.09
Aug 15, 2024Bank of America Securities
Syndax price target raised to $31 from $30 at BofA
Target:$31.00
+58.3%from $19.58
Aug 15, 2024Barclays
Syndax price target raised to $33 from $32 at Barclays
Target:$33.00
+68.5%from $19.58
Jul 30, 2024Bank of America Securities
Syndax Pharmaceuticals (SNDX) PT Lowered to $30 at BofA Securities
Target:$30.00
+36.4%from $21.99
Jun 28, 2024Jefferies
Jefferies Starts Syndax Pharmaceuticals (SNDX) at Buy
Target:$37.00
+82.1%from $20.32
May 9, 2024Stifel Nicolaus
Syndax Pharmaceuticals (SNDX) PT Raised to $40 at Stifel
Target:$40.00
+78.7%from $22.38
Jan 3, 2023J.P. Morgan
JP Morgan Initiates Coverage On Syndax Pharmaceuticals with Overweight Rating, Announces Price Target of $41
Target:$41.00
+55.7%from $26.32
Dec 12, 2022Goldman Sachs
Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $39
Target:$39.00
+66.7%from $23.39
Dec 12, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $33
Target:$33.00
+59.9%from $20.64

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance